Methods of treating inflammatory diseases by blocking Galectin-3

A method of decreasing or inhibiting inflammation in a subject in need thereof, the method comprising:

• administering to the subject an effective amount of an anti-Gal3 antibody or binding fragment thereof;
• wherein
• the anti-Gal3 antibody or binding fragment thereof comprises (1) a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3;
• and (2) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3, wherein
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 171, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 222, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 249;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 31, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 72, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 113;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 195, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 247, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 292;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 39, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 103, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 165;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 216, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 230, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 267;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 67, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 82, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 166;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 192, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 236, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 270;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 68, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 82, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 167;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 217, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 229, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 293;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 69, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 109, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 168;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 218, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 237, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 294;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 69, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 109, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 168;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 219, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 225, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 295;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 70, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 110, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 169;
• or
• the VL-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 220, the VL-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 227, the VL-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 296;
• the VH-CDR1 comprises an amino acid that comprise SEQ ID NO:
• 43, the VH-CDR2 comprises an amino acid sequence that comprise SEQ ID NO:
• 111, and the VH-CDR3 comprises an amino acid sequence that comprise SEQ ID NO:
• 138;
• and wherein
• administration of the effective amount of the anti-Gal3 antibody or binding fragment thereof decreases or inhibits neutrophil activation and/or migration in the subject, decreases or inhibits cleavage of CD62L expressed by neutrophils, decreases or inhibits IL-8 production in the subject, decreases the number of neutrophils in the subject, and/or modulates expression of myeloperoxidase (MPO), growth-related oncogene α (GROα)/keratinocytes-derived chemokine (KC), Ly6c1, INOS, IL-6, TNFα, IL-1B, Col1A1, aSMA, TGFβ, VEGFA, VEGFB, or any combination thereof, in the subject.